HealthcareServices

Liquid Biopsy For Cancer Diagnostics Sector Forecast Shows Robust Momentum, Climbing to $22.99 Billion With 16.4% CAGR

February 26, 2026February 26, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the liquid biopsy for cancer diagnostics market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Liquid Biopsy For Cancer Diagnostics Market reach by 2030 starting from 2026 levels?

The liquid biopsy for cancer diagnostics market has experienced rapid expansion in recent years. It is anticipated to grow from $10.75 billion in 2025 to $12.52 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.4%. The growth observed in the preceding period can be ascribed to several factors, including the limitations associated with tissue biopsy procedures, an increasing incidence of lung and breast cancer, the early adoption of molecular cancer diagnostics, a heightened demand for early-stage cancer detection, and augmented clinical research in oncology diagnostics.

The market for liquid biopsy in cancer diagnostics is projected to experience swift expansion over the coming years. By 2030, this market is anticipated to reach $22.99 billion, exhibiting a compound annual growth rate (CAGR) of 16.4%. Factors contributing to this growth during the projected period include the broader application of liquid biopsy in standard cancer screening, an increased emphasis on individualized cancer treatment, its heightened utilization in monitoring treatment effectiveness, escalating investments in cancer diagnostic tools, and its widening application in detecting gastrointestinal and ovarian cancers. Key trends for the forecast duration encompass the increasing uptake of liquid biopsy for lung cancer detection, a surge in the use of blood-based methods for cancer screening, a growing need for continuous cancer surveillance, the spread of liquid biopsy applications across numerous cancer varieties, and an escalating clinical preference for diagnostic approaches that are less invasive.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

Which Drivers Are Influencing Long-Term Growth In The Liquid Biopsy For Cancer Diagnostics Market?

The increasing occurrence of cancer is anticipated to fuel expansion in the liquid biopsy for cancer diagnostics market in the future. Cancer, a diverse group of diseases, arises when abnormal cells multiply without control in almost any organ or tissue, extending beyond their normal limits and potentially spreading to other organs or invading adjacent areas. The presence of cancer heightens the demand for diagnostic methods, including early detection of cancer or tumor recurrence, individual patient risk assessment, and treatment monitoring. Liquid biopsy is crucial here because it can portray the entire disease landscape, as tumor cells or their byproducts are shed from all primary or metastatic tumor locations, offering comprehensive and current insights into tumor cell changes, therapeutic goals, and strategies for overcoming treatment resistance. For example, data from May 2024 by the US-based National Cancer Institute indicated approximately 18.1 million cancer survivors in the United States. This number is expected to climb to 22.5 million by 2032. Projections suggest that by 2040, annual new cancer cases will reach 29.9 million, and cancer-related fatalities are estimated to grow to 15.3 million. Consequently, the growing frequency of cancer cases is fueling the expansion of the liquid biopsy for cancer diagnostics market.

How Is The Liquid Biopsy For Cancer Diagnostics Market Divided Into Segments?

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

Which Trends Are Guiding The Evolution Of The Liquid Biopsy For Cancer Diagnostics Market?

Key players within the liquid biopsy market for cancer diagnosis are dedicating their resources to creating novel solutions, including sophisticated liquid biopsy assays. Such an assay is a highly refined diagnostic tool designed to examine different elements in biological fluids like blood, aiming to identify and define particular biomarkers linked to cancer or other conditions. As an illustration, in November 2023, Illumina Inc., a prominent US-based company in DNA sequencing, introduced its ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. This particular research assay is engineered to enable comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) found in blood, using a noninvasive method. The TSO 500 ctDNA v2 assay aims to make integration easier for its users and provide more profound insights for cancer-related investigations.

Which Major Industry Participants Are Leading The Liquid Biopsy For Cancer Diagnostics Market Growth?

Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Liquid Biopsy For Cancer Diagnostics Market?

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Liquid Biopsy For Cancer Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12205&type=smp

Browse Through More Reports Similar to the Global Liquid Biopsy For Cancer Diagnostics Market 2026, By The Business Research Company

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Liquid Biopsy Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Biopsy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopsy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795